MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
T2 Biosystems, Inc. (NASDAQ: TTOO)*
Organization & Developments: T2 Biosystems
Parents
T2 Biosystems, Inc. (NASDAQ: TTOO)*
Children
*Creating a new generation of lab-quality diagnostic tools
*DEVELOPS DIAGNOSTIC INSTRUMENTS FOR THE DETECTION OF FUNGAL PATHOGENS KNOWN TO CAUSE SEPSIS AND HEMOSTASIS.
*Has developed a proprietary magnetic resonance technology platform that enables rapid detection of pathogens, biomarkers, and other abnormalities in patient fluids including blood, plasma, serum, saliva, sputum, and urine.
*T2’s lead product is a rapid detection assay for Candida, a fungal pathogen known to cause blood stream infections and sepsis.
*Ultimately, T2 Biosystems hopes to develop a portable, commercial, handheld system that could be used at a patient's bedside or
*Will be so small and affordable, they will be used in the ER, the ambulance, the physician’s office, even the home and the field
*Within almost any sample, including whole blood, plasma, serum and urine
2020: CMS extends add-on payment to T2 Bio's bacterial panel
2020: COVID-19 Opportunity Knocks, T2 Answers
2020: FDA OKs emergency use of T2 Biosystems COVID-19 test
2020: T2 And COVID-19
2020: T2 Biosystems Announces Fourth Quarter and Full Year 2019 Financial Results
2020: T2 Biosystems Receives Multiyear Innovative Technology Contract from Vizient, Inc.
2021: T2 Biosystems provides strong Q4 & FY20 prelims
2021: T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus_globenewswire
2021: T2 Biosystems: Last Year's R&D Setup Morphing Into Leading 2021 Growth Pick
2022: BARDA awards $4.4M contract to T2 Biosystems_BioWorld. Link to homepage.
2022: T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million
2022: T2 Biosystems Announces Reverse Stock Split Effective Today
2022: T2 Biosystems rises 14% after multiple new studies show rapid disease detection_seekingalpha.com
2023: Nasdaq issues delisting notice to T2 Biosystems
2023: T2 Biosystems announces 1-for-100 reverse stock split (NASDAQ:TTOO)
2023: T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use
2023: T2 Biosystems touts ‘highly differentiated’ products in fight against sepsis
2024: T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
2024: T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing
2024: T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
2024: T2 Biosystems to license sepsis detection tech
2025: T2 Biosystems initiates major layoffs, seeks asset sale
Organization & Developments: T2 Biosystems (Archives 2010-2019)
Jumps
*Key People: T2 BioSystems
Finance & Acquisitions: T2 Biosystems